95 related articles for article (PubMed ID: 17949520)
21. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
24. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
25. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
26. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
27. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
29. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Fergelot P; Rioux-Leclercq N; Patard JJ
Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
31. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
32. [Renal cell carcinoma and prognostic factors].
Edeline J; Rioux-Leclercq N
Ann Pathol; 2008 Oct; 28(5):374-80. PubMed ID: 19068392
[TBL] [Abstract][Full Text] [Related]
33. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
